about
Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050).Synergistic anticancer effects of a bioactive subfraction of Strobilanthes crispus and tamoxifen on MCF-7 and MDA-MB-231 human breast cancer cell lines.An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cellsComparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cellsQuantitative electrochemical detection of cathepsin B activity in breast cancer cell lysates using carbon nanofiber nanoelectrode arrays toward identification of cancer formation.Tamoxifen--the treatment of choice. Why look for alternatives?Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.N-Alkoxy derivatization of indole-3-carbinol increases the efficacy of the G1 cell cycle arrest and of I3C-specific regulation of cell cycle gene transcription and activity in human breast cancer cells.Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects.Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells.Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials.Dietary fat and breast cancer metastasis by human tumor xenografts.Smad4 as a transcription corepressor for estrogen receptor alpha.AP-1, but not NF-kappa B, is required for efficient steroid-triggered cell death in Drosophila.Risk of breast cancer during hormone replacement therapy: mechanisms.Reversal of estrogen-resistance in murine mammary adenocarcinomas.
P2860
Q32043226-E4DBA217-E5FB-4AB1-B773-BBB1227176B7Q34468514-AD53A572-892D-4909-9462-695D318A972FQ34765600-334694E6-15F3-44A8-A2C4-E7AAD3EDEE95Q35872956-B1556C73-53CC-45C7-B498-F71E5765BCF3Q36101408-341DC444-AC49-4A28-A000-E64E338EECBCQ36114445-199D6971-2349-4798-8058-87779627EFE5Q36135073-A095C803-0CE2-4665-8E4E-CD32DA27B324Q36174625-8411C0AC-4FFB-4BCC-AAA4-05ADECB59919Q36364465-F7EC49E0-4925-4C9A-A07D-40451C11F39BQ36400882-22F78C34-10D7-4518-A841-51277A9E0F46Q37140318-ACF96706-987A-4132-AFE6-55F986C58426Q37195192-582180F6-8187-49BD-9B46-6365371C1ADDQ40905525-B9712C4D-F855-4C83-8B90-8B036A36644DQ41056286-B8479A91-6410-4053-8E61-1EC8A63A8248Q44308474-17A4D82A-E3AB-4B8E-B825-460F76232828Q47071241-0E27241E-A909-475F-BA96-1956B2A5B01FQ53292939-2DB7D0A5-A815-48F3-AB83-E06E05BB3EAEQ53421033-3A162512-306A-475C-8D00-03C881F8BDF9
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Endocrine therapy for advanced breast cancer: a review.
@ast
Endocrine therapy for advanced breast cancer: a review.
@en
type
label
Endocrine therapy for advanced breast cancer: a review.
@ast
Endocrine therapy for advanced breast cancer: a review.
@en
prefLabel
Endocrine therapy for advanced breast cancer: a review.
@ast
Endocrine therapy for advanced breast cancer: a review.
@en
P2860
P356
P1476
Endocrine therapy for advanced breast cancer: a review.
@en
P2093
P2860
P2888
P356
10.1007/BF01811960
P407
P577
1992-01-01T00:00:00Z